>

>

Analytical model to understand IP-driven commercial risks to an oncology portfolio

Service Areas
Therapeutic Areas

Oncology

Client Type

Big Pharma

Client Problems

  • What are the biggest IP-driven commercial risks to an oncology portfolio?


  • Which risks are most sensitive to patent, exclusivity, targeted combination, formulation, & line extension assumptions?

What We Did

  • We needed a platform to vary a number of assumptions to learn for ourselves what mattered vs. did not


  • We decided to create a user-friendly Excel model that could handle many IP, commercial, & global assumptions


  • We tested the model to confirm outputs worked as intended


  • We then mined sensitivity scenarios for new insights

Our Results And Insight

  • Interactive, user-friendly Excel model


  • Dynamic timeline of IP protection


  • New insights about IP and the portfolio

See other case studies

Commercial Strategy case studies >

Oncology case studies >

Service Areas Details

Commercial Strategy (Modeling, Intellectual Property)

Therapeutic Areas Details

Oncology (Immuno-oncology)

© 2019, First Principles Advisory Group. All Rights Reserved
SF Bay Area, Denver, Seattle, New York City, Cambridge
First Principles Advisory Group
1290 Howard Street Suite 323
Burlingame, CA 94010
(415) 669-5183
info@fpadvisory.net